{
  "question_stem": {
    "en": "A 64-year-old man comes to the office due to exertional chest pain over the last 6 months. He is a lifelong 1 pack per day cigarette smoker and has a history of type 2 diabetes mellitus and peripheral artery disease. The patient undergoes treadmill exercise stress testing and develops substernal chest pain on moderate exertion accompanied by ECG changes that resolve immediately upon rest. He refuses invasive cardiac testing. The patient is started on low-dose aspirin therapy for secondary prevention of cardiovascular disease but experiences shortness of breath and wheezing with the medication.",
    "zh": "一名64岁男性因过去6个月的劳力性胸痛前来就诊。他终生每天吸烟1包，并有2型糖尿病和周围动脉疾病病史。患者接受跑步机运动负荷试验，中度劳累时出现胸骨下疼痛，伴有心电图改变，休息后立即缓解。他拒绝有创心脏检查。患者开始接受小剂量阿司匹林治疗，以预防心血管疾病的二次发生，但在服用该药后出现呼吸急促和喘息。"
  },
  "question": {
    "en": "Which of the following is the best alternate therapy for this patient?",
    "zh": "以下哪项是该患者的最佳替代治疗方案？"
  },
  "options": {
    "A": {
      "en": "Apixaban",
      "zh": "阿哌沙班"
    },
    "B": {
      "en": "Cilostazol",
      "zh": "西洛他唑"
    },
    "C": {
      "en": "Clopidogrel",
      "zh": "氯吡格雷"
    },
    "D": {
      "en": "Enoxaparin",
      "zh": "依诺肝素"
    },
    "E": {
      "en": "Eptifibatide",
      "zh": "依替巴肽"
    },
    "F": {
      "en": "Naproxen",
      "zh": "萘普生"
    },
    "G": {
      "en": "Warfarin",
      "zh": "华法林"
    }
  },
  "correct_answer": "C",
  "explanation": {
    "en": "This patient's clinical history is consistent with stable angina (angina pectoris) due to underlying coronary heart disease (CHD). Patients with stable angina should be started on aspirin to decrease the risk of adverse cardiovascular events. Aspirin impairs prostaglandin synthesis by irreversibly inhibiting cyclooxygenase (COX). Inhibition of COX-1 in platelets prevents synthesis of thromboxane A2, a potent stimulator of platelet aggregation and vasoconstriction. This helps reduce the risk of occlusive thrombus formation and subsequent myocardial infarction.\n\nSome patients are unable to tolerate aspirin due to exacerbation of preexisting respiratory symptoms (eg, rhinitis, asthma) or development of allergic reactions (eg, urticaria, angioedema, anaphylaxis). In these patients, alternate antiplatelet agents should be used for prevention of cardiovascular events. Clopidogrel irreversibly blocks the P2Y₁₂ component of ADP receptors on the platelet surface and prevents platelet aggregation. Clopidogrel is as effective as aspirin for prevention of cardiovascular events and should be used in patients with aspirin allergy.\n\n(Choices A and G) Apixaban is a direct factor Xa inhibitor that prevents platelet activation and fibrin clot formation. Warfarin inhibits an enzyme required for synthesis of active vitamin K, resulting in decreased synthesis of vitamin K-dependent clotting factors (II, VII, IX, and X). Both apixaban and warfarin are typically used for prevention and/or treatment of thromboembolic events, not coronary artery disease.\n\n(Choice B) Cilostazol is a phosphodiesterase inhibitor that is occasionally used in patients with symptomatic peripheral vascular disease (ie, claudication).\n\n(Choice D) Low molecular weight heparins (LMWHs; enoxaparin, dalteparin) are indirect thrombin inhibitors that bind with antithrombin and convert it from a slow to a rapid inactivator of thrombin and factor Xa. They are used in patients with ACUTE CORONARY SYNDROME (unstable angina or myocardial infarction) but have no role in the management of patients with stable angina.\n\n(Choice E) Eptifibatide is a platelet glycoprotein IIb/IIIa inhibitor that inhibits the final common pathway of platelet aggregation. Eptifibatide is occasionally used in some patients with ACUTE CORONARY SYNDROME, but it is not used for patients with stable CHD.\n\n(Choice F) Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that is used for pain management in patients with osteoarthritis. Use of both nonselective and selective COX-2 NSAIDs increases the risk of adverse cardiovascular events.\n\nEducational objective:\nClopidogrel irreversibly blocks the P2Y₁₂ component of ADP receptors on the platelet surface and prevents platelet aggregation. Clopidogrel is as effective as aspirin in the prevention of cardiovascular events in patients with coronary heart disease.",
    "zh": "该患者的病史与由于潜在冠心病 (CHD) 引起的稳定性心绞痛 (心绞痛) 相符。 稳定性心绞痛患者应开始服用阿司匹林，以降低不良心血管事件的风险。阿司匹林通过不可逆地抑制环氧合酶 (COX) 来损害前列腺素的合成。抑制血小板中的 COX-1 可防止血栓烷 A2 的合成，血栓烷 A2 是血小板聚集和血管收缩的有效刺激物。这有助于降低闭塞性血栓形成和随后发生心肌梗死的风险。\n\n由于先前存在的呼吸系统症状（例如，鼻炎、哮喘）恶化或发生过敏反应（例如，荨麻疹、血管性水肿、过敏反应），一些患者无法耐受阿司匹林。 在这些患者中，应使用替代抗血小板药物来预防心血管事件。 氯吡格雷不可逆地阻断血小板表面上 ADP 受体的 P2Y₁₂ 成分，并防止血小板聚集。 氯吡格雷在预防心血管事件方面与阿司匹林一样有效，应在对阿司匹林过敏的患者中使用。\n\n（选项 A 和 G）阿哌沙班是一种直接的 Xa 因子抑制剂，可防止血小板激活和纤维蛋白凝块形成。 华法林抑制合成活性维生素 K 所需的酶，导致维生素 K 依赖性凝血因子（II、VII、IX 和 X）的合成减少。阿哌沙班和华法林通常用于预防和/或治疗血栓栓塞事件，而不是冠状动脉疾病。\n\n（选项 B）西洛他唑是一种磷酸二酯酶抑制剂，偶尔用于有症状性周围血管疾病（即跛行）的患者。\n\n（选项 D）低分子量肝素（LMWHs；依诺肝素、达肝素）是间接的凝血酶抑制剂，与抗凝血酶结合，并将其从凝血酶和 Xa 因子的缓慢灭活剂转化为快速灭活剂。 它们用于患有急性冠状动脉综合征（不稳定型心绞痛或心肌梗死）的患者，但在稳定型心绞痛患者的治疗中不起作用。\n\n（选项 E）依替巴肽是一种血小板糖蛋白 IIb/IIIa 抑制剂，可抑制血小板聚集的最终共同途径。 依替巴肽偶尔用于某些患有急性冠状动脉综合征的患者，但不用作稳定型 CHD 患者。\n\n（选项 F）萘普生是一种非甾体抗炎药 (NSAID)，用于治疗骨关节炎患者的疼痛。 使用非选择性和选择性 COX-2 NSAID 都会增加不良心血管事件的风险。\n\n教育目标：\n氯吡格雷不可逆地阻断血小板表面上 ADP 受体的 P2Y₁₂ 成分，并防止血小板聚集。 氯吡格雷在预防冠心病患者的心血管事件方面与阿司匹林一样有效。"
  },
  "summary": {
    "en": "This question assesses the appropriate antiplatelet therapy for a patient with stable angina who is intolerant to aspirin. It requires knowledge of different antiplatelet mechanisms and their indications.\n\nThe best approach is to identify the patient's condition (stable angina), the contraindication to aspirin (respiratory symptoms), and then select an alternative antiplatelet agent that is effective for secondary prevention in this setting. Clopidogrel is the appropriate alternative.",
    "zh": "本题评估了对阿司匹林不耐受的稳定型心绞痛患者的适当抗血小板治疗。 它需要了解不同的抗血小板机制及其适应症。\n\n最好的方法是确定患者的状况（稳定型心绞痛）、阿司匹林的禁忌症（呼吸系统症状），然后选择一种在这种情况下对二级预防有效的替代抗血小板药物。氯吡格雷是合适的替代方案。"
  },
  "tags": "Stable angina; Antiplatelet therapy; Aspirin intolerance; Clopidogrel; Coronary artery disease; Cardiology; Pharmacology",
  "category": "CVS",
  "question_id": "1828",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\CVS 23\\1828",
  "extracted_at": "2025-11-05T12:02:40.306173",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T16:52:51.542075",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}